To aid in the advancement of clinical research and the development of therapeutic strategies for treating patients with multiple sclerosis, Verana Health®, a digital health company elevating quality in real-world data (RWD), has announced today that it is developing QdataTM MS, a Neurology Qdata module (MS).

The news was released in advance of the CNS Summit 2022, which will take place from November 17-20 in Boca Raton, Florida.

Neurology Qdata is a collection of high-quality, human-curated datasets that record information about real-world diseases, their treatments, and their results. Qdata MS is being extracted from the American Academy of Neurology’s Axon Registry® and will be made available through Verana Health’s real-world evidence (RWE) service offerings. One of the largest and fastest-growing real-world clinical data registries in neurology is the Axon Registry, which is handled by Verana Health’s VeraQTM population health data engine. One of the largest longitudinal multiple sclerosis datasets for research usage, the Qdata MS module is expected to include de-identified, curated RWD from roughly 30,000 patients diagnosed with MS as it progresses through development.

Multiple sclerosis affects the central nervous system, which includes the brain, spinal cord, and optic nerves (CNS). This disorder strikes without warning and causes the immune system to assault the central nervous system, interfering with information flow. According to a 2019 study supported by the National Multiple Sclerosis Society, there are about 1 million persons living with MS in the United States. That is significantly higher than the number found in a similar national survey conducted in 1975. Women have a roughly threefold higher risk of developing MS than men do.

Source: Prnewswire